stockrowQIAGEN N.V.
QGEN Healthcare Diagnostics & Research
QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024.
- Revenue
- +0.28%
- EPS
- +7.94%
- Free cash flow
- +30.5%
- Total debt
- +13.8%
Quarter to June 2026, against a year earlier
Follow QGEN
Alert me
QIAGEN N.V. (QGEN) EBITDA
QIAGEN N.V.'s EBITDA for fiscal 2025 was $663.0M, up 107.6% from $319.4M in fiscal 2024. Over the twelve months to 30 June 2026 it was $651.0M. Over the past ten years it has ranged from $246.1M (fiscal 2019) to $877.3M (fiscal 2021); the current reading is higher than 82% of that period. QIAGEN N.V. ranks 13th of 49 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $663.0M | 107.56% |
| FY2024 | $319.4M | (50.51%) |
| FY2023 | $645.4M | (16.56%) |
| FY2022 | $773.6M | (11.83%) |
| FY2021 | $877.3M | 38.43% |
| FY2020 | $633.8M | 157.54% |
| FY2019 | $246.1M | (51.61%) |
| FY2018 | $508.6M | 28.87% |
| FY2017 | $394.6M | 18.75% |
| FY2016 | $332.3M | (14.99%) |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $183.5M | 34.74% |
| Mar 2026 | $136.2M | (9.09%) |
| Dec 2025 | $149.8M | (17.38%) |
| Sep 2025 | $181.4M | 5.43% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ICLR ICON PLC compare | $1.1B |
| RVTY Revvity Inc. compare | $775.8M |
| QGEN QIAGEN N.V. | $651.0M |
| MEDP Medpace Holdings, Inc. compare | $634.5M |
| CRL Charles River Laboratories International, Inc. compare | $553.0M |
| RDNT RadNet, Inc. compare | $307.7M |
| BLLN BillionToOne, Inc. compare | $55.6M |
| GRAL GRAIL, Inc. compare | −$400.6M |
| GH Guardant Health, Inc. compare | −$444.9M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on QGEN
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement